RxDoctor Payments Data

Gregory Desimone, DO

Family Medicine · Las Vegas, NVNPI 1851785687

Payments from drug & device makers

$766in general payments, 2019–2025

Across 47 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$205
  • Novo Nordisk$160
  • AstraZeneca$106
  • Pfizer$65
  • Johnson & Johnson$48
  • Biohaven Pharmaceutical Holding Company Ltd.$41
  • plus $140 from 6 others

What the payments were for

  • Food & beverage$766100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$766 in reported general payments places this provider in the 65th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$29,932
Medicare patients
136
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$168,537
JardianceEmpagliflozin72$103,393
TrulicityDulaglutide73$92,267
EliquisApixaban86$87,869
MounjaroTirzepatide22$31,109
XareltoRivaroxaban16$21,307
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$18,074
MyrbetriqMirabegron28$17,976
SymbicortBudesonide/Formoterol Fumarate27$12,556
Spiriva RespimatTiotropium Bromide14$10,932
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$8,553
Arnuity ElliptaFluticasone Furoate14$5,681
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$4,716
Atorvastatin Calcium427$3,978
Albuterol Sulfate HfaAlbuterol Sulfate123$3,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$160$168,537100 claims
Boehringer IngelheimJardiance, Spiriva Respimat$205$114,32486 claims
PfizerEliquis$65$87,86986 claims
Johnson & JohnsonXarelto$48$21,30716 claims
Astellas Pharma US IncMyrbetriq$14$17,97628 claims
AstraZenecaSymbicort$106$12,55627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →